≥95%byHPLC
Filippakopoulos,P., etal.,Nature. 468(7327):1067-73(2011).
ApplicationReference(s):
1. ThepolycombgroupproteinBMI-1inhibitorPTC-209isapotentanti-myelomaagentaloneorincombinationwithepigeneticinhibitorstargetingEZH2andtheBETbromodomains(2017)
2. AnalysisofChromatinOpeninginHeterochromaticNon-SmallcellLungCancerTumor-InitiatingCellsinRelationtoDNA-DamagingAntitumorTreatment (2017)
3. NotchInhibitionEnhancesCardiacReprogrammingbyIncreasingMEF2CTranscriptionalActivity (2017)
4. PanobinostatactssynergisticallywithibrutinibindiffuselargeBcelllymphomacellswithMyD88L265mutations (2017)
5. Erratum:BRD4isahistoneacetyltransferasethatevictsnucleosomesfromchromatin (2017)
6. TargetingBETproteinsimprovesthetherapeuticefficacyofBCL-2inhibitioninT-cellacutelymphoblasticleukemia (2017)
7. UncoveringBRD4hyperphosphorylationassociatedwithcellulartransformationinNUTmidlinecarcinoma (2017)
8. DeacetylaseinhibitorsrepressSTAT5-mediatedtranscriptionbyinterferingwithbromodomainandextra-terminal(BET)proteinfunction (2015)
9. GLI2-dependentc-MYCupregulationmediatesresistanceofpancreaticcancercellstotheBETbromodomaininhibitorJQ1 (2015)
10. BETbromodomaininhibitorsblockgrowthofpancreaticcancercellsinthree-dimensionalcollagen (2014)
11. Dualkinase-bromodomaininhibitorsforrationallydesignedpolypharmacology (2014)
12. BETbromodomainproteininhibitionisatherapeuticoptionformedulloblastoma (2013)